MKGAY News Alert Merck Kgaa Unsp ADR (MKGAY) 31.9000 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck Kgaa Unsp ADR (MKGAY) 31.9000 $MKGAY

Sigma-Aldrich Buyout by Merck KGaA Gets Antitrust Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:30AM CST
Sigma-Aldrich Corporation (SIAL) and Merck KGaA (MKGAY) announced that latter has obtained antitrust clearance from the US FTC for its previously announced acquisition of Sigma-Aldrich.
ROC: 79.11 (-0.01), SIAL: 137.16 (-0.01), MTX: 71.84 (+0.11)

Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance
PR Newswire - Tue Dec 23, 8:44AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with the acquisition expired on December 22, 2014, thereby completing the U.S. HSR Act antitrust notification and review requirement for the acquisition of the Company by Merck KGaA, Darmstadt, Germany.
SIAL: 137.16 (-0.01)

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 88.18 (+0.89), CLDX: 17.08 (-0.18), CYCC: 0.69 (+0.01), IMMU: 4.41 (+0.13), EBS: 27.64 (+1.28), INCY: 71.57 (+1.99), TGTX: 16.03 (+0.33), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GILD: 91.29 (+1.84), CELGZ: 3.34 (-0.01)

Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.49 (unch), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), CLDX: 17.08 (-0.18), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), MNTA: 11.42 (-0.06), PVCT: 0.85 (-0.02), VICL: 1.03 (+0.02), AZN: 70.44 (+0.26), DCTH: 1.36 (+0.01), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

Photoresists and Photoresist Ancillaries Market for Semiconductors & Integrated Circuits, Printed Circuit Boards and Other Applications - 2014 Global Industry Analysis
M2 - Tue Dec 16, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/fpxq7k/photoresists_and) has announced the addition of the "Photoresists and Photoresist Ancillaries Market for Semiconductors & Integrated Circuits, Printed Circuit Boards and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Growth in the global semiconductor industry is anticipated to drive the photoresists and photoresist ancillaries market worldwide. Photoresists are indispensable components in the process of multi-layer wiring configuration in semiconductor manufacturing and high density packaging. Trends in dynamic display technologies are further estimated to boost the photoresists and photoresist ancillaries market in the near future. However, environmental and occupational health hazards associated with photoresists and photoresist ancillaries are expected to hamper the global market growth in the near future. Upcoming nanoelectromechanical systems (NEMS) are projected to offer high opportunities for market players in the next few years. In terms of revenue, semiconductor & integrated circuits (ICs) emerged as the largest application segment of the global photoresists and photoresist ancillaries market in 2013. The segment accounted for over 55% share in 2013. Semiconductor & ICs segment is anticipated to remain the largest application in the near future. Major end-use industries for semiconductor & ICs application segment include data processing (laptops, servers and personal computers), communication (smartphones, mobile phones, broadband internet and fixed-line telephones), automotive, consumer electronics (music players, household appliances and gaming consoles) and industrial electronics. Printed circuit boards was the second-largest segment for photoresists and photoresist ancillaries in 2013. Demand for photoresists and photoresist ancillaries from other applications that include MEMS, NEMS and sensors is projected to rise at a moderate pace in the next few years. Scope of the Report Photoresists Market - Product Segment Analysis - g-line and i-line - KrF - ArF dry - ArF immersion Photoresist Ancillaries Market - Product Segment Analysis - Antireflective coatings - Photoresist developers - Edge bead removers - Others (Including primers or adhesion promoters and specialty solvents) Photoresists and Photoresist Ancillaries Market - Application Analysis - Semiconductors and integrated circuits (ICs) - Printed circuit boards (PCB) - Others (Including MEMS, NEMS, sensors etc.) Companies Mentioned - Avantor Performance Materials Inc. - E. I. du Pont de Nemours and Company - FUJIFILM Electronics Materials Co. Ltd. - JSR Corporation - LG Chem Ltd - Merck KGaA - Shin-Etsu Chemical Co. Ltd. - Sumitomo Chemical Co. Ltd. - TOKYO OHKA KOGYO CO. LTD. - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/fp...esists_and

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/kspvsg/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Genentech, Inc. - MedImmune, LLC - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Merck KGaA - Oncolytics Biotech Inc. - Panacea Biotec Limited - PCI Biotech AS - Glycotope GmbH - VentiRx Pharmaceuticals, Inc. - Immunovative Therapies, Ltd. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/ks...rrent_head
ONCY: 0.49 (unch), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), NVS: 93.91 (+0.66)

EMD Serono Continues Leadership Role in Product Integrity by Launching Product Tracking Program and Check My Meds(TM) Smartphone App
PR Newswire - Wed Dec 10, 7:00AM CST
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced that it has serialized all of its major brands in the U.S., which helps patients and physicians to authenticate the company's medicines at the unit level. This new serialization initiative builds on the company's track record of product integrity and will launch in advance of requirements set forth in new legislation for pharmaceutical companies to serialize their prescription drug products at the unit level by 2017.

Global Cellular Imaging Markets Report 2014
M2 - Wed Dec 10, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/tj5773/cellular_imaging) has announced the addition of the "Global Cellular Imaging Markets Report 2014" report to their offering. The Global Cellular Imaging Market is dominated by Beckton Dickinson and Company, Danaher Corporation, Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., GE Healthcare, Merck KGAA, Olympus Corpopration, Perkinelmer, Inc., Promega Corporation. The global cell analysis market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Most of the players in the cell analysis instruments market are collaborating with companies and educational institutes in order to offer the products with better software also. The cell analysis market is expected to grow steadily in the forecast period. The major factor driving the growth is improved accuracy of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing prevalence of cancer, getting help from the government bodies in the form of investments, funds and grants, improved informatics services, availability of better reagents and image analysis instruments are propelling the growth of the market. However, the major market restraints include enormous capital investments and shortage of skilled labor for high content screening procedure. The biggest opportunities for this market is the growing APAC market, high content screening services provided by CRO's, automation in cancer research for its early detection and reducing cost of the cancer treatment. Key Topics Covered: 1. Executive summary 2. Introduction 3. Market Analysis 4. Single cell analysis market by technology 5. Single cell analysis market by products 6. Single cell analysis market by field of study 7. Single cell analysis market by applications 8. Single cell analysis market by end users 9. Regional Market Analysis 10. Company Developments 11. Major Company Profiles - Agilent Technologies, Inc. - Beckton, Dickinson And Company - Danaher Corporation - GE Healthcare - Merck KGaA - Olympus Corpopration - Perkinelmer, Inc - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/tj...ar_imaging
A: 41.13 (-0.24), SIAL: 137.16 (-0.01), DHR: 86.79 (-0.27)

Global Pollen Allergy Clinical Trials Review Report 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/ml2jdj/pollen_allergy) has announced the addition of the "Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Merck KGaA - Laboratorios LETI S.L. - Merck & Co., Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Circassia Pharmaceuticals plc - Anergis SA Clinical Trial Overview of Top Institutes / Government - Chiba University - University of Yamanashi - Nippon Medical School Hospital - University of Zurich - Medical University of Vienna - Imperial College London - Johann Wolfgang Goethe University Hospitals - Jikei University School of Medicine - The University of Tokushima - University of Fukui For more information visit http://www.researchandmarkets.com/research/ml...en_allergy
MRK: 57.46 (+0.25)

Sigma-Aldrich's stockholders grants approval for its USD140/share acquisition by Merck KGaA
M2 - Mon Dec 08, 6:59AM CST
Sigma-Aldrich (NASDAQ:SIAL) said on Friday that its stockholders have voted to adopt the merger agreement with and into Merck KGaA, Darmstadt, Germany at a special meeting of stockholders held earlier today.
SIAL: 137.16 (-0.01)

Sigma-Aldrich Stockholders Approve Acquisition By Merck KGaA
PR Newswire - Fri Dec 05, 11:30AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders held earlier today. Sigma-Aldrich stockholders also approved, on an advisory, non-binding basis, compensation that may become payable to named executive officers as a result of the acquisition.
SIAL: 137.16 (-0.01)

EMD Serono Awards Grant for Growth - Countdown for Accepting Applications
CNW Group - Thu Dec 04, 1:30AM CST
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, reminded today that there is just one month remaining for scientists leading innovative research projects to apply for grants as part of the EMD Serono Grant for Growth Innovation (GGI). Grants totalling up to $500,000 will be awarded to one or more selected projects.

Global Cell Isolation/Cell Separation Market Outlook to 2019: Market is Expected to Reach $5.1 Billion by 2019 from $2.5 Billion in 2014
M2 - Mon Dec 01, 7:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjwjzt/cell) has announced the addition of the "Cell Isolation/Cell Separation Market by Product, Cell Type, Technique, Application & by End user - Forecast to 2019" report to their offering. The global cell isolation market is expected to reach $5.1 billion by 2019 from $2.5 billion in 2014, growing at a CAGR of 15.8% from 2014 to 2019. The Asian region, stem cell isolation, and magnetic activated cell separators are expected to serve as new revenue pockets for the cell isolation market in the coming five years. Major factors contributing to growth of the cell isolation market include the increasing usage of cell isolation in cancer research, expanding biotechnology and biopharmaceutical industries, technological advancements, high prevalence of infectious diseases, and rising aging population are likely to propel the growth of this market. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in November 2013, National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) provided up to $1.5 million funds to STEMCELL Technologies (Canada) for the development of cell isolation technology, to augment the research of Human Immunodeficiency Virus (HIV) and other infectious diseases. The relatively untapped markets of the Asian region and advent of microfluidics in cell isolation have opened an array of opportunities for the cell isolation market. H owever, reluctance amongst researchers to use advanced cell isolation techniques and high cost of instruments are expected to restrain the growth of this market. Moreover, there are various ethical issues related to embryonic stem cell research, which is expected to hinder the growth of this market to some extent. Scope of the Report - Product (Reagent, Media, Bead, centrifuge) - Cell Type (human, stem cell, animal) - Technique (Filtration, Surface Marker) - Application (Research, IVD) - End user (Hospital, Biotechnology) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Market, By Product 8 Cell Isolation Market, By Cell Type 9 Cell Isolation Market, By Techniques 10 Cell Isolation Market, By Applications 11 Cell Isolation Market, By End User 12 Cell Isolation Market, By Geography 13 Competitive Landscape 14 Company Profiles - Beckman Coulter (Subsidiary of Danaher Corporation) - Becton Dickinson and Company - GE Healthcare (A Fully Owned Subsidiary of General Electric Company) - Merck Millipore (A Segment of Merck KGAA) - Miltenyi Biotec - Pluriselect Life Science - Sigma-Aldrich Corporation - Stemcell Technologies - Terumo BCT (A Subsidiary of Terumo Corporation) - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/fjwjzt/cell
GE: 25.83 (-0.05), SIAL: 137.16 (-0.01), MRK: 57.46 (+0.25), DHR: 86.79 (-0.27)

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014
M2 - Mon Dec 01, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/22wv9l/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - Adamis - Aeterna Zentaris - Alethia Biotherapeutics - Amgen - AnGes MG - Antoxis - Aphios - Armour - Arno - Astellas Pharma - Astex - AstraZeneca - Ausio - Bavarian Nordic - Bayer - Beta Pharma - Bio-Cancer Treatment International - Biscayne - Boehringer Ingelheim - Celldex - CureTech - CytoVac A/S - DexTech Medical - Enceladus BV - Endo - EndoCeutics - Endocyte - Errant Gene - Fujifilm - Genentech - Glactone Pharma - GlaxoSmithKline - GTx - Harbor - Hybrigenics - Incuron - Io - Isis - Johnson & Johnson - Kinex - Medivation - Medvio Eurasia - Merck KGaA - Millennium - NewLink Genetics - Novartis AG - Oncogenex - Orion Oyj - Orphagen - Oxford BioMedica - Panacela Labs - Tokai - Viamet For more information visit http://www.researchandmarkets.com/research/22wv9l/hormone
JNJ: 104.59 (+0.31), NLNK: 39.08 (+1.36), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)

Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.41 (+0.13), AMGN: 160.67 (+3.15), RGLS: 14.78 (+0.24), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), PVCT: 0.85 (-0.02), CANF: 3.70 (+0.01), DCTH: 1.36 (+0.01), NVS: 93.91 (+0.66), XLRN: 38.80 (+0.80)

Germany's Merck sticking with consumer healthcare business
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 9:35AM CST


Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 4.18 (-0.22), BIB: 122.51 (+3.83), INCY: 71.57 (+1.99), PFE: 31.42 (-0.03), IBB: 299.80 (+5.12), DRGS: 53.60 (unch), BIND: 5.73 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), ONTY: 1.89 (+0.01), ECYT: 6.33 (+0.24), BIS: 47.26 (-1.74), CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), ARIA: 6.81 (+0.15), IRY: 47.28 (-0.01), IXJ: 100.54 (+0.55), FPRX: 26.12 (+0.07)

Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen
Brian Coleman - at Seeking Alpha - Fri Nov 21, 11:21AM CST

PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), CGEN: 8.58 (-0.17), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66)

Is Pfizer Spending Enough On R&D?
Tom Armistead - Seeking Alpha - Wed Nov 19, 3:36PM CST
R&D is a primary growth driver for pharmaceutical companies. Pfizer (NYSE: PFE ) CEO Ian Read, newly appointed at the time, announced draconian cuts to this sensitive expense area on 1/31/2011, and followed through, cutting it from $9.4 billion...
PFE: 31.42 (-0.03), AZN: 70.44 (+0.26)

EMD Millipore Launches Kit for Analyzing NFkB Translocation by Imaging Flow Cytometry
PR Newswire - Wed Nov 19, 6:00AM CST
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today introduced the Amnis® NFkB Translocation kit, which allows researchers to better study the nuclear translocation of NFkB, a transcription factor that plays a central role in regulating key mammalian cell processes, including proliferation, inflammation, immune and stress responses. The new kit uses imaging flow cytometry to obtain statistically significant quantitative assessment of NFkB translocation, as well as visual identification of the translocation at a single-cell level.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 101

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 0

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 39

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 111

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 25

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
IAS Marks 42 Years Amid Germany Religious Freedom Win

Updated Category News Views 96

Bagpipes, country roads and a gathering from six continents made this far more than a routine anniversary reception. The International Association of Scientologists marked its 42nd anniversary at Saint Hill in East Grinstead, England, with thousands of Scientologists and guests arriving as autumn settled over West Sussex. That sort of turnout is a visible statement of...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 41

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 126

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading
Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 125

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading

Top 5 Most Recently Viewed Articles

Novartis Faces Setback as Entresto Generic Approved

Updated Category News Views 393

Novartis' Legal Challenges with Entresto Generic Novartis, a leading pharmaceutical company, recently encountered a significant setback in its attempts to block the launch of a generic version of its heart-failure medication, Entresto. A federal judge in Washington, D.C., ruled against Novartis', effectively paving the way for MSN Pharmaceuticals to release its generic...

Continue Reading
Walk-On's Partners with Port Royal for Expansive Growth

Updated Category News Views 581

Walk-On's Sports Bistreaux Announces Major Development Deal Walk-On's Sports Bistreaux is thrilled to announce a pivotal partnership with Port Royal Brands, marking a significant step forward in its expansion plans. This exciting collaboration will encompass the development of 20 new restaurants, aiming to bring the spirit of family-friendly sports dining to new...

Continue Reading
Gabelli Healthcare & Wellness Trust Announces Quarterly $0.17 Distribution

Updated Category News Views 152

Gabelli Healthcare & Wellness Trust Declares Cash Distribution The Board of Trustees of The Gabelli Healthcare & Wellness Trust (NYSE: GRX) has announced a cash distribution of $0.17 per share. This distribution is set to be paid to common shareholders on a specified date. The Board's decision reflects ongoing efforts to provide regular income to investors. Distribution...

Continue Reading
Faraday Future Prepares for Third Quarter Earnings Call

Updated Category News Views 119

Faraday Future Announces Earnings Conference Call Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) is excited to share the timeline for its scheduled earnings conference call focused on its third quarter results for 2024. This highly anticipated call will occur after market hours, specifically on a Wednesday evening, at 5:00 p.m. Pacific Time. Investors and...

Continue Reading
Chicagoland Leaders Rally to Support Local Black Businesses

Updated Category News Views 123

Community Leaders Unite for Local Black Businesses In a powerful display of solidarity, community leaders and clergy in Chicagoland are calling on the City Council to take decisive action in support of local Black-owned businesses. One business at the heart of this effort is Island Furs, a beloved fixture that has proudly served the community for over 30 years. The...

Continue Reading